Pioneer of Stem Cell Automation—Interview with Dr. Li Tao, an expert customer of Robot 365 cell industry

　　Sino-US Cell: The Pioneer of Stem Cell Automation—Interview with Dr. Li Tao, Chairman of Sino-US Cell, a National Leading Talent in the Cell Industry

　　Zhongxu Bio : Artificial Intelligence Boosts the Intelligent and Healthy Development of the Cell Industry—Interview with Zhuo Jiahui, Chairman of Shenzhen Zhongxu Medical Group

　　Xiankangda Biology : The upgrade of digital intelligence promotes the industrial application of cell factories—Interview with Dr. Xie Haitao, Chairman of Xiankangda Group

　　Red Coral Pharmaceutical : The intelligent transformation of the biopharmaceutical industry is the general trend—Interview with Wang Zhongyu, Chairman of Red Coral Pharmaceutical Group

　　CUHK 365 : Artificial Intelligence Empowers Biomedicine to Lead Scientific Innovation Momentum - Interview with Xiao Weipeng, General Manager of Cross-Strait Biomedical Industry Base

　　Guangdong Medical University : Industry-University-Research Integration Promotes Intelligent Life Medicine—Interview with Dean Lin Lin, School of Biomedical Engineering, Guangdong Medical University

　　Songshan Lake Management Committee : Advanced Manufacturing in Guangdong-Hong Kong-Macao Greater Bay Area is flourishing in Songshan Lake—Interview with Yi Kangming, Management Committee of Songshan Lake National High-tech Industrial Park

　　The digital and intelligent upgrade path of the cell industry from point to surface

　　Sino-US Cell is one of the world's leading cell R&D and production companies, founded by the national cell industry leader (former Dr. Li Tao, chief R&D director of Beike Biotech). In recent years, Sino-US Saier has further increased investment in digitization, automation, intelligence, etc., deeply cultivated "intelligent" manufacturing, boldly explored the construction and digital transformation of intelligent robots, and achieved positive results.

　　Zhongmei Saier Biotechnology (Guangdong) Co., Ltd. (hereinafter referred to as "Zhongmei Saier") is a high-tech enterprise specializing in cell R&D, production, and cell technology support services in China. Its customers include leading brands in the cell and pharmaceutical industries at home and abroad. . Sino-US Saier not only leads the development of the cell industry with its cutting-edge technology and strong technological innovation strength, but also actively explores digital transformation in recent years, with remarkable results. In 2021, Sino-US Saier and Robot 365 Company will build a "lighthouse factory" for cell cultivation robots in Songshan Lake, which means Sino-US Saier's intelligent digital transformation has made great progress. In this special topic, Dr. Li Tao, Chairman of Sino-US Saier, a national leading talent in the cell industry, shared in detail the company's thinking and exploration of the intelligent digital transformation of the cell industry.

Dr. Li Tao, Chairman of Sino-US Saier

　　Reporter: First of all, please give a brief introduction to Sino-US Saier.

　　Li Tao : Sino-US Cell was established in 2014. It is one of the world's leading cell R&D and production companies. It is one of the few cell product and cell drug R&D companies in China with completely independent intellectual property rights. The company has an expert technical team with outstanding achievements in the field of immune cells and stem cells, with strong technical strength. The R&D laboratory has invested tens of millions of yuan, and has built a complete cell preparation center, quality control center, cell repository, technology R&D center and animal experiments. In the center, the high-standard laboratory site covers an area of ​​more than 2,000 square meters.

　　Reporter: In your opinion, what are the notable characteristics of the cell R&D field where Sinomax is located? In view of Sinomax's own development and needs, what changes and pain points are faced?

　　Li Tao : Since there are many types and types of cell products, the traditional cell preparation process has significant human factors, and it is difficult to control the uniformity and consistency of products. These diversified products mean that there are many varieties of processes. . Therefore, from the perspective of specific business processes, the product is not contaminated and the quality requirements are uniform. In addition to the particularity and complexity of the process, cell products often need to be launched to the market in a shorter time. The industry often adopts "human sea tactics" to improve efficiency and fill "various and small" production scenarios, but the turnover rate of personnel is high, Rising labor costs and difficulty in controlling efficiency and quality are becoming common problems faced by the industry.

　　As a globalized R&D enterprise, Sino-American Saier has continuously increased its production capacity under the rapid development of the company's business, but the process optimization is relatively slow, resulting in high and complicated experiments, which is not in line with the management concept of lean production. Therefore, in general, in order to meet the needs of multiple varieties and small batches and the challenges of faster time-to-market, it has become a trend for the entire cell industry to upgrade in the direction of automation, intelligence and digitization. As a representative of the cell industry As an enterprise, we have implemented intelligent digital transformation as an important development strategy of the company very early, and it is currently in steady progress.

Sino-US Cell R&D laboratory scene

　　Reporter: Please talk about your understanding of the "cell industry" and analysis of industry development?

　　Li Tao : The history of the development of the cell industry has a long history. In the last century, there were some clues. The real development of the cell industry from international to domestic. Everyone in the industry knows the cooperative medical treatment of the cell industry in the future medical field. Including the improvement of health care and anti-aging to a considerable height, it may still be after this century. After entering this century, the country has promulgated a large number of policies and regulations to promote the cell industry and improve the development trend of the industry, which provides a lot of legal or policy guarantees for promoting the orderly and healthy development of this industry. The current development should be the momentum is very good. In the near future, including our promulgation of such policies in the Guangdong-Hong Kong-Macao Bay Area, the Shenzhen Municipal Government, including Nanshan District, has issued relevant policies to support the development of the cell industry. Internationally, the top ten scientific and technological breakthroughs in scientific and technological progress selected by scientific journals every year, including the Nobel Prize winners in recent years, have many achievements in the cell industry. There are many here in tumor treatment, including A major breakthrough in basic research. From a general trend, it represents the core of our new technological revolution or the development direction of translational medicine and regenerative medicine in the future.

Robotic 365 Cell Preparation Workstation

　　Reporter: What do you think of the future direction of the cell industry and the trend of automation?

　　Li Tao : In fact, I think the future of our cell industry, the country's general direction of cell development, the productization of cells is a trend. If we want to make products into medicines, it is based on the special properties of cells themselves. One is how it can achieve the uniform consistency of the product, and the product is not contaminated. Compared with chemical drugs and other biological drugs, cell drugs have some special requirements. In fact, we have also been troubled by these special requirements for a long time. How can we achieve uniform products? The indicators of drug efficacy and cells themselves include basic biological properties in the West, as well as the safety and effectiveness of cells. It all depends on a very special technology, otherwise it may be difficult to get a complete solution. The cooperation with the company that happens to be doing a fully automated cell culture system with Robot 365 can solve the long-standing problems of our company and even the entire industry, and may be completely solved. And we have also made a long-term attempt in the early stage, and it has indeed achieved the effect we expected.

Sino-US Saier and Robot 365 reached a strategic cooperation

　　Reporter: What insights did you have during the cooperation process?

　　Li Tao : Our cooperation is very pleasant. From the top leadership and staff and the technical staff who cooperate with us, we have a very happy cooperation. The cooperation in the early stage is very good. Of course, our current technology is still in the process of gradual improvement. I believe that we will be completely improved in the near future, and I am very satisfied with their services.

　　Reporter: What other explorations of Sino-US Saier need to be intelligently upgraded next? What are the directions and goals of the key upgrades?

　　Li Tao : Starting this year, we will also start to focus on the upgrade of the overall cell factory intelligence. From cell storage, preparation, transportation and other links need to be continuously optimized, through reasonable optimization to avoid unnecessary waste, reduce possible risks, etc. In the future, further intelligent and digital upgrades will be realized. In short, we will further improve the intelligent decision-making capabilities of the cell industry, such as building an intelligent production scheduling system, so that the entire production can seamlessly complete the production plan arrangement, and the company's operations will not be affected due to the turnover of personnel. Digitalization Transformation is a process of continuous optimization, improvement and upgrading. We will further use digital tools such as the industrial Internet, big data, and artificial intelligence to improve and continue to promote production management efficiency, and ultimately empower the experience of digital transformation to the entire industrial ecology.